TGM2 and cranioectodermal dysplasia: Antibodies against gliadin-peptides and the enzyme transglutaminase-2 (TG2) are highly-specific diagnostic markers of CeD, and a CD4+ T cell response towards post-translationally modified gluten peptides has been described.